The isolates comprised five groups of genetically characterized pneumococci: (i) those resistant to erythromycin and clindamycin [erm(B) genotype]; (ii) those resistant to erythromycin, but susceptible to clindamycin [mef(A) genotype]; (iii) those resistant to tetracycline [tet(M) genotype]; (iv) those with decreased susceptibility to levofloxacin [mutations in gyr(A) and par(C), combined with efflux activity]; and (v) those resistant to trimethoprim-sulphamethoxazole [mutations in the dihydrofolate reductase (DHFR) gene as well as modifications within sul(A), which encodes dihydropteroate synthase (DHPS)]. They were collected from patients with bacteraemia, communityacquired respiratory tract infections or nosocomial pneumonia during international surveillance studies between 1997 and 1999. 5 Only one isolate, which was considered clinically significant according to local criteria, per patient was studied.
A total of 215 S. pneumoniae isolates were selected that were resistant to erythromycin: 157 carried the erm(B) gene and 58 the mef(A) gene. All isolates with erm(B) displayed the MLS B phenotype, while all of those with mef(A) had the M phenotype.
All 240 tetracycline-resistant S. pneumoniae isolates studied carried the tet(M) gene and none the tet(O) gene.
Twenty-five S. pneumoniae isolates were selected that had a decreased susceptibility to levofloxacin (MIC у 2 mg/L). 5 Ten of 16 isolates with a levofloxacin MIC of 4 mg/L demonstrated mutations within par(C) encoding Ser-79ǞPhe, while six of 16 demonstrated mutations encoding Asp-83ǞAsn. All 16 isolates demonstrated mutations within gyr(A) encoding either a Ser-81ǞPhe or a Ser-81ǞTyr amino acid change. None of these mutations was found in any of the nine isolates with levofloxacin MICs of 2 mg/L and ciprofloxacin MICs of 4 mg/L. A mutation in par(E) was found to result in the amino acid change Ile-460ǞVal in 18 of the 25 isolates tested. No alteration was found in GyrB. Reserpine lowered ciprofloxacin MICs by between one and four doubling dilutions in 20 of 25 isolates tested with a ciprofloxacin MIC у 4 mg/L. Therefore, an efflux system probably contributed to the decreased ciprofloxacin susceptibility in most of the isolates tested.
All 50 S. pneumoniae isolates that were resistant to trimethoprim-sulphamethoxazole were also resistant to the two drugs separately. The DHFR genes were sequenced and all isolates displayed the amino acid change Ile-100ǞLeu, as described previously. 6 With regard to sulphonamide resistance, sequence comparisons of the chromosomal DHPS gene of resistant and susceptible clinical pneumococcal isolates revealed duplications of either three or six bases, resulting in the repetition of one or two amino acids in the region from Arg-58 to Tyr-63 of the DHPS of resistant isolates, as described previously. 
The comparative activities of the 22 compounds tested are listed in the Table. These data show that faropenem was one of the most potent agents with an MIC 90 р 0.25 mg/L. The highest MIC observed was 0.5 mg/L, indicating that all isolates tested, including those with a decreased susceptibility to penicillin, were susceptible to the drug, based on a provisional breakpoint of Ͻ1 mg/L. Furthermore, faropenem also showed significant activity against the genetically characterized S. pneumoniae isolates that were not susceptible to antibiotics commonly used in antipneumococcal therapy, i.e. macrolides, tetracyclines, quinolones and co-trimoxazole. In addition, Boswell and colleagues 2 have shown that faropenem exhibits significant bactericidal activity and has a good post-antibiotic effect on S. pneumoniae isolates. Based on all of the data collected to date, faropenem appears to be a promising new antimicrobial agent and warrants further clinical investigation. 
